Biomax Announces Collaboration with Global Vaccine Leader

FALMOUTH, Mass.--(BUSINESS WIRE)--July 26, 2005--Today Biomax announces the successful completion of the first year's implementation and use of the Biomax Optimized Research Environment(SM) enterprise modules at sanofi pasteur in Toronto, Canada. The Biomax enterprise modules, BioRS data integration & retrieval and Pedant-Pro sequence analysis pipeline, support the sanofi pasteur's Integrated Genomics Platform for their core scientific team conducting ongoing in-silico research for vaccines to prevent cancer and infectious diseases.

"Over a year ago, we were fortunate to have the opportunity to respond to a highly complex and detailed RFP issued by sanofi pasteur," said Pat Blake, President of Biomax Solutions Inc. "We knew that sanofi pasteur was the global leader in vaccines for human health and would be a great partner, so we worked very hard to win their confidence." He went on to say, "Our success in this collaboration was critical to executing our new complex disease research support strategy."

“Over a year ago, we were fortunate to have the opportunity to respond to a highly complex and detailed RFP issued by sanofi pasteur”

Biomax software enables the data integration and configuration of a wide variety of bioinformatics workflows in a scaleable and consistent manner. The software is sufficiently open-ended, allowing it to link to additional in-house applications and data sources. The protein-centric focus of the Pedant product helps to quickly amass a comprehensive view of the targets of interest and to bring them forward to help advance multiple projects.

Dr. Klaus Heumann, CEO of Biomax Informatics AG, the German development company, said "This collaboration is an excellent example of how bioinformatics is playing an increasingly important role in supporting complex disease research and establishing information-based medicine. We are excited to see how our products are enabling the pharmaceutical industry to bring health-improving products to market more quickly."

Biomax is proud to have met the challenge that enabled sanofi pasteur to perform a complete suite of bioinformatics analyses in a very efficient manner, and look forward to a continued partnership with this global leader in vaccine research and development.

About Biomax Solutions, Inc.

Biomax Solutions, Inc. (BSI) is an integrator of bioinformatics software development companies. BSI sells, markets, manages channels for, implements and supports the delivery of a broad range of software and services to scientists and laboratories around the globe. BSI also provides a full range of professional services including custom bioinformatics software development. Customers include pharmaceuticals, biotech companies, academics and government research organizations in Europe and the U.S. More information is available at www.biomaxsolutionsinc.com.

About Biomax Informatics AG.

Biomax, a recognized pioneer in the development of customized bioinformatics solutions, was founded in 1997 as a spin-off of the GSF-MIPS academic research group, now the German Research Center for Environment and Health-Institute for Bioinformatics (GSF-IBI). Founded by Prof. Dr. H. W. Mewes, Prof. Dr. D. Frishman and Dr. K. Heumann, Biomax developed a broad portfolio of bioinformatics solutions, including the well-known Pedant-Pro(TM) Sequence Analysis Suite, the BioRS(TM) Data Integration and Retrieval System, and other bioinformatics tools and services used in metabolic analysis, proteomics, and gene expression analysis. Additional information about Biomax can be found at the company's site on the World Wide Web at www.biomax.com.